TRC105 for Liver Cancer That Has Not Responded to Sorafenib
NCT01375569
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
11
Enrollment
NIH
Sponsor class
Conditions
Hepatocellular Carcinoma
Hepatocellular Cancer
Carcinoma, Hepatocellular
Interventions
DRUG:
TRC105
Sponsor
National Cancer Institute (NCI)